GSK Hungary's Claire Roger discusses the value of ethical promotion both in improving transparency and benefiting all stakeholders. She further describes the strategic role and economic impact of GSK’s vaccine plant in Gödöllő and growth opportunities in HIV.
Given that you’ve only recently arrived in May 2015, Claire, what priorities have been at the top of your agenda since stepping in as general manager?
The highest growth prospects are actually currently coming from the HIV segment, further driven by the two new drugs we launched in this area last year.
